StockData
Boundless Bio, Inc. logo

Boundless Bio, Inc. (BOLD) stock

BOLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$2.41+0.00 (0.00%)

Close on Nov 17, 2026Market cap $54.82MP/E –Yield –

Boundless Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Boundless Bio's operating income for the twelve months ending Jun 30, 2026 was -$68.01M. For fiscal 2025 it was -$63.55M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$63.55M–
FY2024Dec 31, 2024-$73.27M–
FY2023Dec 31, 2023-$54.80M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.38M–
Q1 FY2026Mar 31, 2026-$14.48M–
Q4 FY2025Dec 31, 2025-$14.00M–
Q3 FY2025Sep 30, 2025-$15.15M–
Q2 FY2025Jun 30, 2025-$17.06M–
Q1 FY2025Mar 31, 2025-$17.34M–
Q4 FY2024Dec 31, 2024-$18.28M–
Q3 FY2024Sep 30, 2024-$18.72M–
Q2 FY2024Jun 30, 2024-$19.39M–
Q1 FY2024Mar 31, 2024-$16.88M–
Q4 FY2023Dec 31, 2023-$13.80M–
Q3 FY2023Sep 30, 2023-$14.95M–
Q2 FY2023Jun 30, 2023-$13.96M–
Q1 FY2023Mar 31, 2023-$12.09M–

More Boundless Bio figures

See a number that looks wrong?